Vol. 6, Issue 2 (2017)

Author(s):
Sergiy Fedorov

Abstract:
Arrhythmogenic right ventricular dysplasia is a cause of sudden death in young people and athletes. The purpose of this study was to review of modern aspects of management of arrhythmogenic right ventricular dysplasia. Pharmacological options in ARVD treatment consist of antiarrhythmic agents, beta-blockers, and heart failure drug therapy. Implantable defibrillator therapy is the most logical therapeutic strategy for patients with ARVC/D, because the natural history is primarily characterized by the risk of SCD and, only secondarily, by contractile dysfunction leading to progressive heart failure.